M&A activity is going beyond big pharma acquisitions with Supernus Pharmaceuticals and Indivior Pharmaceuticals reaching a stock deal that the companies call a merger of equals. The combined company’s portfolio will have 11 commercialized products in addiction, attention-deficit hyperactivity disorder, depression, and Parkinson’s disease.

The post Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company appeared first on MedCity News.